BR112018009714A8 - ligantes de tnf aperfeiçoados - Google Patents
ligantes de tnf aperfeiçoadosInfo
- Publication number
- BR112018009714A8 BR112018009714A8 BR112018009714A BR112018009714A BR112018009714A8 BR 112018009714 A8 BR112018009714 A8 BR 112018009714A8 BR 112018009714 A BR112018009714 A BR 112018009714A BR 112018009714 A BR112018009714 A BR 112018009714A BR 112018009714 A8 BR112018009714 A8 BR 112018009714A8
- Authority
- BR
- Brazil
- Prior art keywords
- tnf
- polypeptides
- bind
- compounds
- necrosis factor
- Prior art date
Links
- 239000011230 binding agent Substances 0.000 title 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 150000005829 chemical entities Chemical class 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Organic Insulating Materials (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Abstract
a presente invenção se refere a sequências de aminoácidos, compostos e polipeptídeos que se ligam ao fator de necrose tumoral alfa (?tnf? ou ?tnf-alfa?). em particular, a presente invenção se refere aos domínios variáveis únicos de imunoglobulina de cadeia pesada melhorados (também aqui referidos como "isv" ou "isvds") que se ligam ao fator de necrose tumoral alfa, assim como às proteínas, polipeptídeos e outras construções, compostos, moléculas ou entidades químicas que compreendem, tais isvds, jutamente com os ligantes de tnf.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562254375P | 2015-11-12 | 2015-11-12 | |
| PCT/EP2016/077595 WO2017081320A1 (en) | 2015-11-12 | 2016-11-14 | Improved tnf binders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112018009714A2 BR112018009714A2 (pt) | 2018-11-21 |
| BR112018009714A8 true BR112018009714A8 (pt) | 2019-02-26 |
Family
ID=57348648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018009714A BR112018009714A8 (pt) | 2015-11-12 | 2016-11-14 | ligantes de tnf aperfeiçoados |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US10544211B2 (pt) |
| EP (2) | EP3191511B1 (pt) |
| JP (2) | JP6962915B2 (pt) |
| KR (2) | KR20240029115A (pt) |
| CN (1) | CN108473563B (pt) |
| AU (2) | AU2016352943B2 (pt) |
| BR (1) | BR112018009714A8 (pt) |
| CA (2) | CA3005085A1 (pt) |
| CL (1) | CL2018001291A1 (pt) |
| CO (1) | CO2018005915A2 (pt) |
| CR (1) | CR20180311A (pt) |
| CY (1) | CY1120303T1 (pt) |
| DK (1) | DK3191511T3 (pt) |
| DO (1) | DOP2018000122A (pt) |
| EC (1) | ECSP18042569A (pt) |
| ES (1) | ES2662418T3 (pt) |
| GT (1) | GT201800095A (pt) |
| HK (1) | HK1248716A1 (pt) |
| HR (1) | HRP20171949T1 (pt) |
| HU (1) | HUE035805T2 (pt) |
| IL (2) | IL310373A (pt) |
| LT (1) | LT3191511T (pt) |
| MA (1) | MA41653A (pt) |
| MD (1) | MD3191511T2 (pt) |
| ME (1) | ME02954B (pt) |
| MX (1) | MX2018005992A (pt) |
| NO (1) | NO2768984T3 (pt) |
| PE (1) | PE20181317A1 (pt) |
| PH (1) | PH12018501025A1 (pt) |
| PL (1) | PL3191511T3 (pt) |
| PT (1) | PT3191511T (pt) |
| RS (1) | RS56676B1 (pt) |
| SG (1) | SG11201803975SA (pt) |
| SI (1) | SI3191511T1 (pt) |
| TN (1) | TN2018000159A1 (pt) |
| WO (1) | WO2017081320A1 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| HUE031828T2 (en) | 2011-06-23 | 2017-08-28 | Ablynx Nv | Procedures for Predicting, Detecting, and Reducing Aspiration Protein Interference in Assays Containing Immunoglobulin Variable Single Domain |
| KR20230053002A (ko) | 2014-05-16 | 2023-04-20 | 아블린쓰 엔.브이. | 개선된 면역글로불린 가변 도메인 |
| NO2768984T3 (pt) * | 2015-11-12 | 2018-06-09 | ||
| GB201522394D0 (en) | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibodies |
| BR112022009799A2 (pt) | 2019-12-06 | 2022-08-16 | Ablynx Nv | Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina alvejando tnfalfa e il-23 |
| JP2023505490A (ja) | 2019-12-06 | 2023-02-09 | アブリンクス・エヌ・フェー | ＴＮＦαおよびＯＸ４０Ｌを標的とする免疫グロブリン単一可変ドメインを含むポリペプチド |
| CN112300289B (zh) * | 2019-12-30 | 2022-06-10 | 中国药科大学 | RGD4C融合抗TNFα纳米抗体蛋白、制备方法及其应用 |
| EP4263602A1 (en) * | 2020-12-18 | 2023-10-25 | Ablynx N.V. | Polypeptides comprising immunoglobulin single variable domains targeting il-6 and tnf-alpha |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1589107T3 (da) | 1992-08-21 | 2010-04-26 | Univ Bruxelles | Immonuglobuliner uden lette kæder |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| EP1027439B1 (en) | 1997-10-27 | 2010-03-17 | Bac Ip B.V. | Multivalent antigen-binding proteins |
| BR9907950A (pt) | 1998-02-19 | 2001-12-18 | Xcyte Therapies Inc | Composições e processos para regulagem deativação de linfócitos |
| US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| EP3299393A1 (en) | 2002-11-08 | 2018-03-28 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| RU2357974C2 (ru) | 2003-01-10 | 2009-06-10 | Аблинкс Н.В. | Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами |
| ATE414106T1 (de) | 2003-06-30 | 2008-11-15 | Domantis Ltd | Pegylierte single-domain-antikörper (dab) |
| ATE485307T1 (de) | 2003-11-07 | 2010-11-15 | Ablynx Nv | Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung |
| WO2006040153A2 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease |
| MX2007006593A (es) | 2004-12-02 | 2008-03-04 | Domantis Ltd | Anticuerpos de dominio simple anti-il 1r1 y sus usos terapeuticos. |
| PL1888641T3 (pl) * | 2005-05-18 | 2012-05-31 | Ablynx Nv | Białka wiążące albuminę surowicy |
| NZ563392A (en) | 2005-05-20 | 2009-12-24 | Ablynx Nv | Improved Nanobodies(TM) for the treatment of aggregation-mediated disorders |
| DE102005023617A1 (de) * | 2005-05-21 | 2006-11-23 | Aspre Ag | Verfahren zum Mischen von Farben in einem Display |
| JP5049973B2 (ja) | 2005-08-30 | 2012-10-17 | アクトジェニックス・エヌブイ | 慢性全腸炎の治療のための、抗−ＴＮＦα産生乳酸菌 |
| JP2009517069A (ja) | 2005-12-01 | 2009-04-30 | ドマンティス リミテッド | インターロイキン１受容体１型に結合する競合ドメイン抗体フォーマット |
| EA200801170A1 (ru) | 2005-12-01 | 2008-12-30 | Домантис Лимитед | Форматы неконкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа |
| FR2894741B1 (fr) | 2005-12-08 | 2009-12-04 | Centre Nat Etd Spatiales | Chaine de reception par satellite |
| EP2441838A3 (en) | 2006-01-24 | 2013-07-10 | Domantis Limited | Fusion proteins that contain natural junctions |
| EP2057191A1 (en) | 2006-08-18 | 2009-05-13 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
| EP2097449A1 (en) | 2006-12-05 | 2009-09-09 | Ablynx N.V. | Peptides capable of binding to serum proteins |
| BRPI0812298A2 (pt) | 2007-05-24 | 2016-05-24 | Ablynx Nv | sequência de aminoácidos direcionada contra rankl e polipeptídeos compreendendo a mesma para o tratamento de transtornos e doenças ósseas. |
| US8975382B2 (en) | 2007-11-27 | 2015-03-10 | Ablynx N.V. | Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors |
| DE102008023620A1 (de) | 2008-05-15 | 2009-11-19 | Mettler-Toledo (Albstadt) Gmbh | Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf |
| CN102099378B (zh) | 2008-05-16 | 2016-01-20 | 埃博灵克斯股份有限公司 | 针对CXCR4和其他GPCRs的氨基酸序列以及包含所述氨基酸序列的多肽 |
| US20110301335A1 (en) * | 2009-02-19 | 2011-12-08 | Stephen Duffield | Anti-tnfr1 polypeptides, antibody variable domains & antagonists |
| CA2758191C (en) | 2009-04-10 | 2015-06-30 | Ablynx N.V. | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders |
| WO2010130832A2 (en) | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions |
| CN102574914A (zh) | 2009-07-16 | 2012-07-11 | 葛兰素集团有限公司 | 改进的抗血清清蛋白结合性单可变区 |
| US9120855B2 (en) | 2010-02-10 | 2015-09-01 | Novartis Ag | Biologic compounds directed against death receptor 5 |
| CA2831415A1 (en) | 2011-03-28 | 2012-10-04 | Ablynx Nv | Bispecific anti-cxcr7 immunoglobulin single variable domains |
| CA2839779C (en) | 2011-06-23 | 2020-10-06 | Ablynx Nv | Serum albumin binding proteins |
| HUE031828T2 (en) | 2011-06-23 | 2017-08-28 | Ablynx Nv | Procedures for Predicting, Detecting, and Reducing Aspiration Protein Interference in Assays Containing Immunoglobulin Variable Single Domain |
| EP2987806A3 (en) | 2011-08-17 | 2016-07-13 | Glaxo Group Limited | Modified single variable domain antibodies with reduced binding to anti-drug-antibodies |
| WO2014111550A1 (en) | 2013-01-17 | 2014-07-24 | Glaxosmithkline Intellectual Property Development Limited | Modified anti-serum albumin binding proteins |
| KR20230053002A (ko) * | 2014-05-16 | 2023-04-20 | 아블린쓰 엔.브이. | 개선된 면역글로불린 가변 도메인 |
| NO2768984T3 (pt) | 2015-11-12 | 2018-06-09 |
-
2012
- 2012-10-19 NO NO12841612A patent/NO2768984T3/no unknown
-
2016
- 2016-11-13 MA MA041653A patent/MA41653A/fr unknown
- 2016-11-14 CA CA3005085A patent/CA3005085A1/en active Pending
- 2016-11-14 LT LTEP16798122.4T patent/LT3191511T/lt unknown
- 2016-11-14 PL PL16798122T patent/PL3191511T3/pl unknown
- 2016-11-14 CR CR20180311A patent/CR20180311A/es unknown
- 2016-11-14 WO PCT/EP2016/077595 patent/WO2017081320A1/en active Application Filing
- 2016-11-14 EP EP16798122.4A patent/EP3191511B1/en active Active
- 2016-11-14 HU HUE16798122A patent/HUE035805T2/en unknown
- 2016-11-14 PE PE2018000766A patent/PE20181317A1/es unknown
- 2016-11-14 SI SI201630013T patent/SI3191511T1/en unknown
- 2016-11-14 CA CA3234178A patent/CA3234178A1/en active Pending
- 2016-11-14 JP JP2018524836A patent/JP6962915B2/ja active Active
- 2016-11-14 MX MX2018005992A patent/MX2018005992A/es unknown
- 2016-11-14 US US15/501,011 patent/US10544211B2/en active Active
- 2016-11-14 EP EP17184686.8A patent/EP3266798A3/en active Pending
- 2016-11-14 ME MEP-2017-291A patent/ME02954B/me unknown
- 2016-11-14 IL IL310373A patent/IL310373A/en unknown
- 2016-11-14 CN CN201680076588.6A patent/CN108473563B/zh active Active
- 2016-11-14 ES ES16798122.4T patent/ES2662418T3/es active Active
- 2016-11-14 DK DK16798122.4T patent/DK3191511T3/en active
- 2016-11-14 TN TNP/2018/000159A patent/TN2018000159A1/en unknown
- 2016-11-14 BR BR112018009714A patent/BR112018009714A8/pt active Search and Examination
- 2016-11-14 AU AU2016352943A patent/AU2016352943B2/en active Active
- 2016-11-14 MD MDE20170066T patent/MD3191511T2/ro unknown
- 2016-11-14 KR KR1020247005963A patent/KR20240029115A/ko active Application Filing
- 2016-11-14 RS RS20171299A patent/RS56676B1/sr unknown
- 2016-11-14 PT PT167981224T patent/PT3191511T/pt unknown
- 2016-11-14 IL IL259269A patent/IL259269B1/en unknown
- 2016-11-14 SG SG11201803975SA patent/SG11201803975SA/en unknown
- 2016-11-14 KR KR1020187016731A patent/KR102641194B1/ko active IP Right Grant
-
2017
- 2017-03-13 US US15/456,824 patent/US9745372B2/en active Active
- 2017-12-01 HK HK18108106.4A patent/HK1248716A1/zh unknown
- 2017-12-15 HR HRP20171949TT patent/HRP20171949T1/hr unknown
- 2017-12-19 CY CY20171101330T patent/CY1120303T1/el unknown
-
2018
- 2018-05-11 GT GT201800095A patent/GT201800095A/es unknown
- 2018-05-11 DO DO2018000122A patent/DOP2018000122A/es unknown
- 2018-05-11 CL CL2018001291A patent/CL2018001291A1/es unknown
- 2018-05-15 PH PH12018501025A patent/PH12018501025A1/en unknown
- 2018-06-05 EC ECIEPI201842569A patent/ECSP18042569A/es unknown
- 2018-06-08 CO CONC2018/0005915A patent/CO2018005915A2/es unknown
-
2021
- 2021-10-14 JP JP2021168871A patent/JP7357038B2/ja active Active
-
2023
- 2023-01-10 AU AU2023200113A patent/AU2023200113A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018009714A2 (pt) | ligantes de tnf aperfeiçoados | |
| MX2023003630A (es) | Aglutinantes de albumina de suero mejorados. | |
| MX2023005374A (es) | Aglutinantes de albumina serica mejorados. | |
| BR112018070998A2 (pt) | proteínas de ligação triespecíficas e/ou trivalentes | |
| MX2019008536A (es) | Aglutinantes de albumina serica mejorados. | |
| DOP2019000011A (es) | Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123 | |
| CY1122564T1 (el) | Μορια δεσμευσης μονhς αλυσιδας που περιλαμβανουν ν-τελικο αβρ | |
| WO2017085172A3 (en) | Improved serum albumin binders | |
| EA201792572A1 (ru) | Антитела к ox40 и их применение | |
| EA201791057A1 (ru) | Антигенсвязывающие молекулы, содержащие тримерный лиганд семейства tnf | |
| MX2017001403A (es) | Constructo de anticuerpo de cadena individual biespecifico con distribucion mejorada de tejido. | |
| EA201400811A1 (ru) | Двойная индуцированная антигеном двухкомпонентная функциональная комплементация | |
| HRP20220531T1 (hr) | Varijabilni fragmenti antitijela koji se umeću i modificirane a1-a2 domene nkg2d liganda | |
| EA201691589A1 (ru) | Стабилизированные основанные на фибронектине каркасные молекулы | |
| MX2021001418A (es) | Produccion de proteinas heteromultimericas usando celulas de mamifero. | |
| EA201691140A1 (ru) | Иммуногенные композиции и вакцины, полученные из рецепторных белков поверхности бактерий | |
| MX2022003507A (es) | Modulos de union que comprenden dominios ehd2 modificados. | |
| EA201991088A1 (ru) | Связывающие пептиды |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |